Business Opportunity
We have produced a series of monoclonal antibodies that bind
to the ubiquitous basement membrane molecule, perlecan. These are useful as
research reagents in various techniques such as ELISAs, immunocytochemistry and
Western blotting to detect the presence and nature of perlecan produced by
various cells. These will also be useful as probes of biological samples and may
have utility as diagnostics of diseases like arthritis and cancer.
Perlecan (HSPG2) is a multi-functional heparan sulfate
proteoglycan, which was originally isolated from Engelbreth-Holm-Swarm (EHS)
tumours. Perlecan is an extracellular matrix molecule and a major component of
basement membranes. It is also found in mesenchymal organs and avascular tissues
such as cartilage. Perlecan have been shown to interact with many growth factors
to stimulate cell adhesion, migration, proliferation and differentiation.
The Market
The global monoclonal antibody (mAbs) market for diagnosis
and as reagents for research is $10 billion. The role of basement membrane
proteoglycans (of which Perlecan is one) in cancer growth and angiogenesis1, as
well as their potential as therapeutic targets in cancer has been described2.
Cancer and arthritis mAbs accounted for over 75% of the total mAbs market. All
the pharma majors now have mAbs projects in their R&D portfolio.
1.Iozzo RV, et al: Mol Cells. 2009 May
31;27(5):503-513. Review.
2.Fuster MM and Esko JD: Nature Rev Can 2005
July, 5:526-542.
The Technology
Immunogen: Perlecan (HSPG2) derived from the human
embryonic kidney cell line (HEK-293). Species reactivity: human, bovine,
not reactive with mouse, sheep, not yet tested in other species.
Clone number: 5D7-2E4
Epitope: Perlecan (HSPG2) protein
core
-.jpg)
Immunocytochemistry of endothelial cells
(C11STH) fixed with 4% paraformaldehyde. The reactivity of 5D7-2E4 for the
presence of perlecan is shown in green (FITC). Nuclei are stained with DAPI
(blue) and actin fibres are stained red (rhodamine-phalloidin).
Applications
- Enzyme-Linked Immunosorbent Assay (ELISA) 0.5-2
μg/ml
- Western Blot (WB: chemi-luminescent detection) 0.05-0.2
μg/ml
- Immunocytochemistry (fixed with methanol, acetone or 4%
para-formaldehyde) 0.5-2 ug/ml
Licensing Opportunity
NewSouth Innovations Pty Ltd is looking for partners to
license the technology on a non-exclusive basis for research purposes, as well
as potential licensees on an exclusive basis for diagnostic and therapeutic
applications in cancer and inflammation.
Please download the PDF of this Technology Brief